Remodulin and Dyskinesia aggravated - a phase IV clinical study of FDA data

Summary:

Dyskinesia aggravated is reported as a side effect among people who take Remodulin (treprostinil sodium), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Opsumit, and have Pulmonary hypertension.

The phase IV clinical study analyzes which people have Dyskinesia aggravated when taking Remodulin. It is created by eHealthMe based on reports of 55,815 people who have side effects when taking Remodulin from the FDA, and is updated regularly.

What is Remodulin?

Remodulin has active ingredients of treprostinil sodium. It is often used in primary pulmonary hypertension. eHealthMe is studying from 55,843 Remodulin users. Check the latest studies of Remodulin.

What is Dyskinesia aggravated?

Dyskinesia aggravated (abnormality or impairment of voluntary movement) is found to be associated with 1,132 drugs and 370 conditions by eHealthMe. Check the latest studies of Dyskinesia aggravated.

On Jul, 14, 2026

55,815 people reported to have side effects when taking Remodulin.
Among them, 19 people (0.03%) have Dyskinesia aggravated.

Could Remodulin cause Dyskinesia aggravated?

Among these 19 people:

How long have people been on Remodulin when they have Dyskinesia aggravated? *

What is the gender of people who have Dyskinesia aggravated when taking Remodulin? *

female: 63.16 %
male: 36.84 %

What is the age of people who have Dyskinesia aggravated when taking Remodulin? *

What are other drugs people take besides Remodulin? *

Opsumit: 7 people, 36.84%
Revatio: 5 people, 26.32%
Lyrica: 4 people, 21.05%
Adempas: 2 people, 10.53%
Tadalafil: 2 people, 10.53%
Macitentan: 2 people, 10.53%
Bactrim: 2 people, 10.53%
Coreg: 1 person, 5.26%
Flolan: 1 person, 5.26%
Fentanyl Transdermal System: 1 person, 5.26%

What are other side effects people have besides Dyskinesia aggravated? *

Dyspnea (difficult or laboured breathing): 5 people, 26.32%
Fluid Retention (an abnormal accumulation of fluid in the blood): 4 people, 21.05%
Death: 3 people, 15.79%
Oxygen Saturation Decreased: 3 people, 15.79%
Diarrhea: 3 people, 15.79%
Dizziness: 3 people, 15.79%
Infusion Site Extravasation (flow of (blood or lymph) from infusion site): 2 people, 10.53%
Musculoskeletal Pain (pain affects the bones, muscles, ligaments, tendons, and nerves): 2 people, 10.53%
Terminal State (the transitional states between life and biological death): 2 people, 10.53%
Drug Hypersensitivity: 2 people, 10.53%

What are the existing conditions these people have? *

Pulmonary Hypertension (increase in blood pressure in the lung artery): 4 people, 21.05%
Urinary Tract Infection: 2 people, 10.53%
Cor Pulmonale Chronic (long lasting enlargement of the right ventricle of the heart): 2 people, 10.53%
Pain: 1 person, 5.26%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 1 person, 5.26%
Depression: 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Remodulin and have Dyskinesia aggravated?

- Check whether Dyskinesia aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Remodulin:

Remodulin (55,843 reports)

Browse all side effects of Remodulin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dyskinesia aggravated:

Dyskinesia aggravated (1,133 drugs)

Browse all the conditions that are associated with Dyskinesia aggravated:

Dyskinesia aggravated (370 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on treprostinil sodium (the active ingredients of Remodulin) and Remodulin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.